441 - The development of a potent, KDR/VEGFR2-sparing RET kinase inhibitor for treating patients with RET-dependent cancers

Autor: Brandhuber, B., Haas, J., Tuch, B., Ebata, K., Bouhana, K., McFaddin, E., Williams, L., Winski, S., Brown, E., Burkhard, M., Nanda, N., Hamor, R., Sullivan, F., Hanson, L., Morales, T., Vigers, G., Wallace, R.D., Blake, J., Andrews, S., Rothenberg, S.M.
Zdroj: In European Journal of Cancer December 2016 69 Supplement 1:S144-S144
Databáze: ScienceDirect
Externí odkaz: